Residents of Port Huron Township are demanding repairs to a crumbling railway overpass near 24th Street and Griswold Road, citing safety concerns due to deteriorating concrete and muddy conditions. The main overpass is owned by Canadian National Railway (CN), which claims the structure is sound but needs maintenance, while a smaller, inoperable overpass is owned by CSX Rail. Community advocate "Trash the Clown" and City Councilwoman Teri Lamb have highlighted the issue, pushing for action from the railway companies.

Veralto Corporation has priced an offering of $725 million in senior notes due 2032 with a 4.850% interest rate, expected to close around June 1, 2026. The company intends to use the estimated net proceeds of $720.6 million for general corporate purposes, including refinancing debt and working capital. This debt issuance follows strong Q1 2026 financial results and an increased full-year EPS guidance.

Morgan Stanley increased its price target for HSBC Holdings (HSBC) from 1,419 GBp to 1,463 GBp, while maintaining an Equal Weight rating. This adjustment comes despite HSBC's fiscal Q1 2026 pretax profit falling short of estimates and the bank raising its credit loss forecast. The article also notes HSBC's underperformance compared to European rivals and a significant loss related to the collapse of a British mortgage lender, which has amplified regulatory scrutiny on the private credit industry.

Thermo Fisher Scientific Inc. (TMO) hosted its annual Investor Day, targeting a bold 7% organic revenue CAGR over the long term, a significant increase from its recent 1% Q1 2026 organic growth. The company emphasized its dominant position in life sciences and declared a quarterly cash dividend of $0.47 per common share. While TMO is considered a strong investment, the article suggests other AI stocks might offer greater upside potential.

Taylor Greenwald, CFO of IBEX Ltd, sold 964 common shares worth $30,867 to cover tax obligations, while simultaneously acquiring 3,333 performance-based shares that converted from PSUs. Following these transactions, Greenwald holds 62,230 common shares. InvestingPro analysis suggests IBEX is undervalued, trading at a low earnings multiple relative to near-term growth, and the company recently reported strong Q3 fiscal 2026 results and authorized a $20 million share repurchase program.

IDEXX Laboratories (IDXX) has integrated its SDMA kidney biomarker, an early kidney disease detector, into its most popular point-of-care chemistry profiles, Catalyst CLIPs. This integration will be rolled out to customers in the US and Canada at no additional cost, providing veterinarians with earlier detection capabilities compared to traditional methods. The move aims to scale the impact of IDEXX's diagnostic innovations through platforms veterinarians already utilize daily.

Stifel analyst Jonathan Block reconfirmed a Buy rating and $210 price target for Align Technology (ALGN) after reviewing an updated financial model and the company's latest 10-Q filing. The updated model incorporated recent clear aligner volume data and Align's Q1 2026 earnings report, which showed revenue of $1.04 billion, a 6.2% year-over-year increase, attributed to record clear aligner shipments and higher selling prices. The company's GAAP EPS for Q1 2026 was $1.57 per diluted share, up from $1.26 in Q1 2025, driven by improved gross margins, a lower tax rate, and share buybacks.

Goldman Sachs reinstated coverage on Medtronic plc (MDT) with a Neutral rating and an $84 price target, noting the stock is appropriately priced at a 10% discount to its large-cap MedTech peers. The firm projects Medtronic's organic revenue to grow in line with the sector average of 5%, but expects more modest earnings growth due to a less favorable product mix for margin expansion. This suggests Medtronic needs stronger top-line growth to achieve comparable bottom-line lift relative to competitors.

William Blair analyst Steve Lichtman initiated coverage on Insulet (PODD) with an Outperform rating, citing the company's attractive valuation after a significant selloff despite near-term growth risks. Lichtman highlighted Insulet's strong revenue trajectory compared to peers, alongside catalysts like salesforce expansion and product development, as reasons for a stronger bull case. However, he also noted potential concerns regarding increased competition and uncertainty about Insulet's ability to capture the type 2 diabetes patient population due to the rise of GLP-1 drugs.

Heico Corp (HEI.A) reported record financial results for Q2 2026, with net income surging by 49% to $233.8 million, or $1.66 per diluted share, significantly exceeding analyst expectations. The company also saw a 25% increase in net sales to $1,375.7 million and strong operating income growth, reaffirming its robust performance in the aerospace and defense industry despite rising costs and increased debt from acquisitions. GuruFocus data indicates that HEI.A is currently undervalued, presenting a potential investment opportunity.